Ilmarinen Mutual Pension Insurance Co lifted its holdings in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 4.5% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 927,000 shares of the biopharmaceutical company’s stock after purchasing an additional 40,000 shares during the quarter. Ilmarinen Mutual Pension Insurance Co’s holdings in Pfizer were worth $23,082,000 as of its most recent filing with the SEC.
Other hedge funds have also made changes to their positions in the company. Horizon Financial Services LLC lifted its position in shares of Pfizer by 174.8% during the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 645 shares in the last quarter. Godfrey Financial Associates Inc. acquired a new stake in shares of Pfizer during the fourth quarter worth about $26,000. YANKCOM Partnership acquired a new stake in shares of Pfizer during the fourth quarter worth about $28,000. HFM Investment Advisors LLC lifted its position in shares of Pfizer by 61.0% during the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 427 shares in the last quarter. Finally, Darwin Wealth Management LLC acquired a new stake in shares of Pfizer during the second quarter worth about $32,000. Institutional investors and hedge funds own 68.36% of the company’s stock.
Analyst Upgrades and Downgrades
Several brokerages have recently issued reports on PFE. Zacks Research raised shares of Pfizer from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $30.00 target price on shares of Pfizer in a report on Monday, March 9th. Royal Bank Of Canada reaffirmed an “underperform” rating and issued a $25.00 target price on shares of Pfizer in a report on Monday, April 20th. CICC Research began coverage on shares of Pfizer in a report on Thursday, April 16th. They issued an “outperform” rating and a $33.00 target price on the stock. Finally, Guggenheim raised their target price on shares of Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a report on Tuesday, March 24th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, eleven have issued a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $28.82.
Pfizer Stock Down 0.2%
Shares of NYSE:PFE opened at $26.16 on Friday. The firm’s 50 day moving average price is $26.79 and its 200 day moving average price is $26.28. The stock has a market cap of $149.07 billion, a price-to-earnings ratio of 19.97 and a beta of 0.35. Pfizer Inc. has a fifty-two week low of $23.06 and a fifty-two week high of $28.75. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67.
Pfizer (NYSE:PFE – Get Free Report) last issued its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. The firm had revenue of $14.45 billion for the quarter, compared to analysts’ expectations of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The firm’s revenue was up 5.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities research analysts predict that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.
Pfizer Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.6%. The ex-dividend date is Friday, May 8th. Pfizer’s dividend payout ratio is currently 131.30%.
Key Headlines Impacting Pfizer
Here are the key news stories impacting Pfizer this week:
- Positive Sentiment: Pfizer and Innovent Biologics announced a global licensing and collaboration deal to research and develop 12 early-stage cancer medicines, with potential value of up to $10.5 billion. The agreement expands Pfizer’s oncology pipeline and could create long-term revenue opportunities. Reuters article
- Positive Sentiment: The companies also described the partnership as a strategic global collaboration covering ADCs and multi-specific antibodies, which suggests Pfizer is strengthening its next-generation cancer portfolio. PR Newswire article
- Positive Sentiment: Recent coverage also highlighted steady early-stage pipeline progress, including a new Phase 1 trial update, reinforcing the view that Pfizer has several development programs moving forward. TipRanks article
- Neutral Sentiment: Bank of America recently lifted its price target on Pfizer to $27 from $26 after stronger quarterly results, indicating slightly improved sentiment but still a cautious overall stance. Yahoo Finance article
Pfizer Profile
Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.
Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.
Featured Articles
- Five stocks we like better than Pfizer
- 3 Stocks Rallying on Micron’s Price Boost: Substance or Hype?
- Snowflake and the Snowballing Impact of its AI Flywheel
- AI’s Biggest Bottleneck Could Make These 2 Stocks Soar
- These 3 Beaten-Down Stocks Just Saw $25 Million in Insider Buying
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
